English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Fathi, A., Dahlke, C., Krähling, V., Kupke, A., Okba, N. M. A., Raadsen, M. P., et al. (2022). Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. medRxiv: the preprint server for health sciences, 2022.02.14.22270168. doi:10.1101/2022.02.14.22270168.

Item is

Files

show Files
hide Files
:
Preprint.pdf (Any fulltext), 4MB
 
File Permalink:
-
Name:
Preprint.pdf
Description:
-
Visibility:
Restricted (Max Planck Institute of Colloids and Interfaces, MTKG; )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show
hide
Locator:
Preprint (Any fulltext)
Description:
-

Creators

show
hide
 Creators:
Fathi, Anahita, Author
Dahlke, Christine, Author
Krähling, Verena, Author
Kupke, Alexandra, Author
Okba, Nisreen M. A., Author
Raadsen, Matthijs P., Author
Heidepriem, Jasmin1, Author              
Müller, Marcel A., Author
Paris, Grigori1, Author              
Lassen, Susan, Author
Klüver, Michael, Author
Volz, Asisa, Author
Koch, Till, Author
Ly, My L., Author
Friedrich, Monika, Author
Fux, Robert, Author
Tscherne, Alina, Author
Kalodimou, Georgia, Author
Schmiedel, Stefan, Author
Corman, Victor M., Author
Hesterkamp, Thomas, AuthorDrosten, Christian, AuthorLoeffler, Felix F.1, Author              Haagmans, Bart L., AuthorSutter, Gerd, AuthorBecker, Stephan, AuthorAddo, Marylyn M., Author more..
Affiliations:
1Felix Löffler, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society, ou_2385692              

Content

show
hide
Free keywords: -
 Abstract: Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. A booster vaccination with MVA-MERS-S is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n=1) and the S2 subunit (n=3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials.

Details

show
hide
Language(s): eng - English
 Dates: 2022-02-152022
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1101/2022.02.14.22270168
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: medRxiv : the preprint server for health sciences
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Cold Spring Harbor : Cold Spring Harbor Laboratory
Pages: - Volume / Issue: - Sequence Number: 2022.02.14.22270168 Start / End Page: - Identifier: ZDB: 3044535-8